Lupin and Zydus Partner for Semaglutide Injection Co-marketing in India

Lupin Limited has signed a Licensing and Supply Agreement with Zydus Lifesciences Limited to co-market the innovative Semaglutide Injection in India. Under this agreement, Lupin will market the product under the brand names Semanext® and Livarise®, while Zydus will continue to market it under SEMAGLYNTM, MASHEMATM, and ALTERMETM. The partnership is designed to expand access to advanced diabetes and weight management therapies across India.

The financial terms of the agreement include upfront licensing fees and milestone payments from Lupin to Zydus. These payments are contingent upon achieving predefined milestones, although specific financial figures are not disclosed in the filing. The agreement grants Lupin semi-exclusive rights to co-market the Semaglutide Injection in India.

The scope of the agreement involves the marketing of the Semaglutide Injection (15 mg/3 ml) with a patient-friendly reusable pen device. This product is indicated for adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It is also indicated for chronic weight management in adults with a body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

The market context for this agreement highlights the growing demand for advanced therapies in the treatment of metabolic disorders in India. The collaboration between Lupin and Zydus aims to leverage Lupin’s extensive reach in the Indian market and Zydus’ robust development capabilities. This partnership is positioned to address unmet patient needs by providing high-quality treatment options for diabetes and weight management.

The timeline for the implementation of this agreement and the achievement of milestones has not been specified in the filing. However, both companies have expressed their commitment to enhancing patient access to these therapies in India. The agreement reflects a strategic move to broaden the availability of innovative treatment options in the Indian healthcare market.

Zydus Lifesciences Limited is an innovation-led global life sciences company with a strong presence in pharmaceuticals and consumer wellness. The company focuses on unlocking new possibilities in life sciences through quality healthcare solutions. Zydus has a significant international presence, including in the United States and India.

Lupin Limited is a global pharmaceutical leader specializing in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company operates in over 100 markets and is committed to improving patient health outcomes through its subsidiaries, including Lupin Diagnostics and Lupin Digital Health.